Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

Woman wearing protective mask

Why Owens & Minor Stock Skyrocketed 55% Today

Investors are excited about the company's revised full-year earnings guidance.

COVID-19 vaccine montage

4 Coronavirus Vaccine Stocks the Bill & Melinda Gates Foundation Is Betting On

Are any of these stocks good bets for other investors?

Man pointing to dollar signs

3 Stocks That Could Double Your Money

And they could do it relatively soon.

Cannabis leaf in front of Canadian flag

Why Canopy Growth Stock Is Sliding Today

The most likely reason: poor financial results from a top rival.

Doctor on phone - telehealth

Is This Hot IPO Stock a Better Buy Than Teladoc Health?

Amwell and Teladoc have a lot in common, but their differences matter most.

Shadow of dollar sign on cannabis pile

The Scariest Number in Aurora Cannabis' Q4 Results

It doesn't bode well for the Canadian cannabis producer's hopes of turning things around.

Female scientist holding 2 test tubes

Why Wave Life Sciences Shares Vaulted Higher Today

Investors liked an analyst's upgrade of the biotech stock.

Cannabis bag

Why Cresco Labs Stock Jumped Today

The company received approval for its tenth cannabis dispensary in Illinois.

Cannabis with stock chart

Why Aurora Cannabis Stock Is Flying High Today

An analyst's upgrade and hopes that better days are on the way are driving the pot stock higher.

$100 bills burning

Is Illumina Making an $8 Billion Blunder?

A lot of investors hate Illumina's planned acquisition of GRAIL. But is the deal really that bad?

Scientist holding test tube

Why Pfizer's Latest Big Win Makes It an Even Better Buy for Retirees

The big drugmaker could soon up its game in the lung cancer market.

Wood blocks forming rocketship

3 Critical Catalysts on the Way for Inovio

With three important milestones just ahead, the biotech stock will likely soar or sink in the near future.

Hand with DNA helix image

Why Illumina Stock Is Sinking Today

Investors are skeptical about the company's latest acquisition.

Test tubes with green arrow pointing up

If You Invested $5,000 in Moderna in January, This Is How Much You'd Have Now

The biotech stock has been a big winner so far this year. And it could be an even bigger winner very soon.

Warren Buffett (TMF photo)

Warren Buffett's 3 Best-Performing Stocks So Far This Year: Are They Buys Now?

These Buffett stocks have all delivered sizzling year-to-date gains. Can they keep the momentum going?

Coronavirus vaccine

3 Best Coronavirus Vaccine Stocks to Buy Right Now

You don't have to take on a huge amount of risk to profit from these solid COVID-19 vaccine leaders.

2 bags of money

Here's the Dividend Stock Most Likely to Double by 2022

The path to making it happen is straightforward.

Female scientist holding COVID-19 vaccine

Better Coronavirus Stock: AstraZeneca or Moderna?

The risk-reward profiles of these COVID-19 vaccine leaders are very different.

COVID-19 vaccine and $100 bills

Why Inovio Stock Is Bouncing Back Today

No news is good news for the coronavirus-focused biotech.

Retired couple walking

3 Dividend Stocks Perfect for Retirees

These stocks have all the ingredients retirees want.